Tag: obligation

If you purchased or acquired securities in Chipotle between February 8, 2024 to October 29, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Caribou (CRBU) To Contact Him Directly To Discuss Their Options

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommended that Regional shareholders vote “FOR”: (1) the approval of the Amended and Restated Agreement and Plan of Merger, dated April 14, 2025 (as amended, the “Merger Agreement”), by and between Regional and SunLink Health Systems, Inc. (the “Merger Proposal”), (2) the approval of the issuance of shares of Regional common stock and Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares (the “Regional Series D preferred stock”) in connection with the merger (the “Share Issuance Proposal”), and (3) the approval to adjourn the Regional special meeting to solicit additional proxies in favor of the Merger Proposal or the Share Issuance Proposal if there are insufficient votes at the time of such adjournment to approve the Merger Proposal or the Share Issuance Proposal.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Crocs (CROX) To Contact Him Directly To Discuss Their Options

If you purchased or acquired stock in Acadia between February 28, 2020 to October 30, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atkore (ATKR)To Contact Him Directly To Discuss Their Options

New York, July 25, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") for its client Garden Stage Limited (NASDAQ: GSIW) (“GSIW” or the “Company”), a Hong Kong-based financial services provider.

CORYDON, Ind., July 25, 2025 (GLOBE NEWSWIRE) -- First Capital, Inc. (the “Company”) (NASDAQ: FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $3.8 million, or $1.13 per diluted share, for the quarter ended June 30, 2025, compared to net income of $2.8 million, or $0.85 per diluted share, for the quarter ended June 30, 2024.

GEELONG, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that Orion Infrastructure Capital ("OIC") has released US$5 million of the US$25 million facility announced on December 23, 2024. As a result of this release, the full US$25 million facility has now been released. Concurrent with this US$5 million tranche, lenders under the US$60 million PIUS loan entered into in May 2023 (“Existing Noteholders”) have also released the final US$400,000 of existing loan reserves, taking reserves released to US$2 million. In connection with this funding tranche, the Company will issue to OIC and Existing Noteholders, penny warrants to purchase an aggregate number of shares equal to 5.0% of the Company’s shares outstanding.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.